GenoSpace

Executive Summary

GenoSpace is a precision medicine software company headquartered in Cambridge, MA, that provides a platform integrating clinical, genomic, and real-world data to bridge clinical research and care, primarily in oncology. Founded in 2010, the company enables community-based practices to automate data collection, match patients to clinical trials, and assess study feasibility, aiming to scale personalized medicine. With a focus on reducing the gap between research and clinical delivery, GenoSpace addresses the growing demand for decentralized clinical trials and real-world evidence in oncology. The platform's ability to streamline data workflows positions it well in the expanding precision medicine market, though the company remains private with limited public financial disclosures. As community oncology practices increasingly adopt digital tools for trial access and data management, GenoSpace has the potential to capture significant market share, provided it continues to secure partnerships and funding to scale its offerings.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major partnership with a large health system or pharmaceutical company for clinical trial matching60% success
• Q4 2026Completion of Series B or C funding round to accelerate product development and market expansion50% success
• Q2 2026Launch of AI-driven trial matching capability that enhances patient-trial fit accuracy70% success